Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
COVID-19
Omicron
SARS-CoV-2
avidity
neutralizing antibodies
vaccines
variants of concern
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
16
09
2022
received:
20
08
2022
accepted:
29
10
2022
pubmed:
2
11
2022
medline:
11
1
2023
entrez:
1
11
2022
Statut:
ppublish
Résumé
We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID-19 naïve and convalescent individuals. Third doses of mRNA COVID-19 vaccines induced a significant increase in potency and breadth of neutralization against SARS-CoV-2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross-neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID-19 convalescents except for BA.4/5. Avidity of RBD-binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences are required to induce high avidity cross-neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments.
Identifiants
pubmed: 36319593
doi: 10.1002/jmv.28268
pmc: PMC9828064
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
mRNA Vaccines
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28268Informations de copyright
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
J Infect Dis. 2022 Dec 28;227(1):35-39
pubmed: 35921532
J Med Virol. 2023 Jan;95(1):e28268
pubmed: 36319593
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
J Infect Dis. 2022 Jun 1;225(11):1905-1908
pubmed: 34963008
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Science. 2021 Mar 25;:
pubmed: 33766944
Lancet Microbe. 2022 Feb;3(2):e81-e82
pubmed: 34901897
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311